ArticleCost effectiveness and resource allocation : C/E2020
Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone.
Article in Cost effectiveness and resource allocation : C/E, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Investigation of the Status of Epidemiology, Pathophysiology, Virology, Clinical Symptoms, Diagnosis, Prevention, Treatment and Classification of Ebola Virus Disease (EVD): A Systematic Review.Infectious disorders drug targets · 2025Pooled it
- Estimating the impact of decreasing vaccination response times for outbreaks of vaccine-preventable diseases in low- and middle-income countries.BMC global and public health · 2026Article
- Contrasting the impact and cost-effectiveness of successive intervention strategies in response to Ebola in the Democratic Republic of the Congo, 2018-2020.BMJ global health · 2025Article
- Gaps and opportunities for data systems and economics to support priority setting for climate-sensitive infectious diseases in sub-Saharan Africa: A rapid scoping review.PLOS global public health · 2025Article
- The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review.Cost effectiveness and resource allocation : C/E · 2024Article
- The cost of public health interventions to respond to the 10th Ebola outbreak in the Democratic Republic of the Congo.BMJ global health · 2023Article
- Understanding public perceptions in social media responses to posts about acute severe hepatitis of unknown etiology in Indonesia: a qualitative study.BMC infectious diseases · 2023Article
- Article
- Economic evaluations of interventions against viral pandemics: a scoping review.Public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2014-2016 Ebola virus disease (EVD) outbreak in West Africa was the largest EVD outbreak recorded, which has triggered calls for investments that would facilitate an even earlier response. This study aims to estimate the costs and health effects of earlier interventions in Sierra Leone.
methodsA deterministic and a stochastic compartment model describing the EVD outbreak was estimated using a variety of data sources. Costs and Disability-Adjusted Life Years were used to estimate and compare scenarios of earlier interventions.
resultsFour weeks earlier interventions would have averted 10,257 (IQR 4353-18,813) cases and 8835 (IQR 3766-16,316) deaths. This implies 456 (IQR 194-841) thousand DALYs and 203 (IQR 87-374) million $US saved. The greatest losses occurred outside the healthcare sector.
conclusionsEarlier response in an Ebola outbreak saves lives and costs. Investments in healthcare system facilitating such responses are needed and can offer good value for money.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.